$PFE has generated 79 mentions from 11 distinct FinTwit voices over the past 12 months, with discussion concentrated among a small group of biotech-focused commentators. @jacobplieth dominates the conversation with 59 mentions, followed by @adamfeuerstein with 26 mentions, while @kaizen_investor, @tig88411109, and @blackpanthercap contribute 3, 2, and 1 mentions respectively. The first mention in the archive appeared on 2025-08-28, with activity continuing through 2026-07-03.

Recent discussion of Pfizer has centered on clinical trial outcomes and pipeline challenges. @adamfeuerstein posted on 2026-06-22 that "$PFE IB6-targeted ADC failed to improve OS in patients with previously treated non-small cell lung cancer," and separately noted "Closely watched Pfizer lung cancer drug falls short in clinical trial." Most recently on 2026-07-03, commentary reflected broader concerns about the company's development strategy.